Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This study is to assess the safety and tolerability, and to assess the preliminary clinical
benefit of NKTR-214 when combined with pembrolizumab (KEYTRUDA®) with or without
chemotherapy.
The study is comprised of two groups; dose optimization and dose expansion cohorts.
Dose Optimization included first-line and second-line advanced or metastatic solid tumors
including non-small cell lung cancer (NSCLC)
The dose expansion cohort will include first-line NSCLC patients.